Cardiology / Pulmonology
Cardiology is one of the first expertise area of Infucare. We provide advanced treatments for PAH.
Our main focus is the treatment of cardiovascular diseases. The field includes any type of disease that is heart-related or that disrupts the normal heart rhythm. Cardiovascular diseases are characterized by high blood pressure, coronary heart disease, arrhythmia or stroke. Infucare specifically carry treatments for Pulmonary arterial hypertension (PAH).
PAH is a is a rare disease that causes an increase in the pulmonary vascular resistance and an increase in blood pressure in the pulmonary circulation. The reduced blood flow through the lungs is accompanied by an insufficient supply of oxygen to the body. As a consequence, patients suffer from lethargy, shortness of breath and a drop in physical performance.
If PAH is left untreated for two or three years after first diagnosis has been made, it will result in life-threatening heart failure.
Early diagnosis and proper treatment are important for the prognosis of the disease and ensuring quality of life. Diagnosis requires additional examination using specialized facilities.
These non-specific symptoms can also present in a broad range of cardiac and pulmonary diseases. Diagnosis requires additional examination using specialized facilities, which can delay commencement of treatment. Delays of two years or more before diagnosis of PAH and the start of treatment are frequent.
Although inhaled and other therapies are used to dilate the pulmonary vessels in the acute phase of PAH, there is currently no curative treatment available for chronic PAH.
To relieve the symptoms, treatment generally involves the use of non-specific medications, such as anticoagulants, diuretics and oxygen, if necessary. Lung transplantation is offered only for those patients where medication has delivered no improvement.
Our committment to PAH care:
Over the last 10 years, Infucare has continuously committed to working alongside healthcare professionals in providing PAH care and treatment offering solutions that are adapted to each patient, ensure continuity of care and anticipate future needs.
As soon as the chronic disease is diagnosed and following prescriptions by a physician, our teams make an active contribution to delivering a sustainable improvement in patient quality of life through the provision of specific infused or inhaled treatments.
We have developed over the years personalized patient support programs.
People with heart disease are more likely to contract an acute respiratory infection. Anyone whose immune system might be weakened by another disease is at risk.
From this conclusion, and given its lenghty experience in the cardiovascular field, Infucare has focused its development projects around infectious lung diseases like tuberculosis (TB) and mycobacterial infections that can be hard to diagnosis and also hard to treat.
Infucare's current focus area is Non Tuberculosis Mycobacteria (NTN) lung infection.
Nontuberculous mycobacteria (NTM) are organisms naturally found in soil and water. In some people, the organism infects the airways and lung tissue leading to disease.
NTM lung infection occurs when a person inhales the organism from their environment. Most people do not become ill but for some susceptible individuals, a slowly progressive and destructive disease can occur.
Diagnosis of NTM lung disease is often delayed, because the symptoms are similar to other lung diseases like COPD, bronchitis or bronchiectasis. However, once NTM infection is suspected, diagnosis is not difficult.
Most people with NTM lung disease experience chronic cough and fatigue. This can make you feel isolated, anxious, or depressed. Treatment is long and often has many side effects.